Ludwig Kappos

Summary

Affiliation: University Hospital
Country: Switzerland

Publications

  1. ncbi Towards a european network for multiple sclerosis trials (ENMST)
    L Kappos
    Outpatient Clinic Neurology Neurosurgery, University Hospitals, Basel, Switzerland
    Mult Scler 9:627-9. 2003
  2. ncbi 10 years of interferon beta-1b (Beta feron therapy
    Ludwig Kappos
    Outpatient Clinic Neurology-Neurosurgery, University Hospital, Petersgraben 4, 4031 Basel, Switzerland
    J Neurol 252:iii1-iii2. 2005
  3. ncbi Genomics and proteomics: role in the management of multiple sclerosis
    Ludwig Kappos
    Outpatient Clinic Neurology Neurosurgery, University Hospital, Petersgraben 4, 4031 Basel, Switzerland
    J Neurol 252:iii21-iii27. 2005
  4. ncbi Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS
    L Kappos
    University of Basel, Basel, Switzerland
    Neurology 67:944-53. 2006
  5. ncbi Effect of BG-12 on contrast-enhanced lesions in patients with relapsing--remitting multiple sclerosis: subgroup analyses from the phase 2b study
    Ludwig Kappos
    Department of Neurology, University Hospital Basel, Basel, Switzerland
    Mult Scler 18:314-21. 2012
  6. ncbi Modeling the cumulative genetic risk for multiple sclerosis from genome-wide association data
    Joanne H Wang
    Department of Neurology, University of California San Francisco, San Francisco, CA 94143 0435, USA
    Genome Med 3:3. 2011
  7. ncbi MRI characteristics are predictive for CDMS in monofocal, but not in multifocal patients with a clinically isolated syndrome
    Jessica M Nielsen
    MS Center, Department of Neurology, VU Medical Center, Amsterdam, The Netherlands
    BMC Neurol 9:19. 2009
  8. ncbi Effect of drugs in secondary disease progression in patients with multiple sclerosis
    Ludwig Kappos
    Departments of Neurology and Research, University Hospitals, Kantonsspital, Petersgraben 4, CH 4031 Basel, Switzerland
    Mult Scler 10:S46-54; discussion S54-5. 2004
  9. ncbi Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials
    L Kappos
    Outpatient Clinic Neurology Neurosurgery, University Hospital Basel, Petersgraben 4, 4031 Basel, Switzerland
    Neurology 63:1779-87. 2004
  10. ncbi A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis
    Ludwig Kappos
    Department of Neurology, University Hospital, University of Basel, Switzerland
    N Engl J Med 362:387-401. 2010

Detail Information

Publications110 found, 100 shown here

  1. ncbi Towards a european network for multiple sclerosis trials (ENMST)
    L Kappos
    Outpatient Clinic Neurology Neurosurgery, University Hospitals, Basel, Switzerland
    Mult Scler 9:627-9. 2003
    ..Collaboration with existing international organizations and institutions, especially the Sylvia Lawry Centre for MS Research, as well as with similar initiatives in North America and other parts of the world is envisaged...
  2. ncbi 10 years of interferon beta-1b (Beta feron therapy
    Ludwig Kappos
    Outpatient Clinic Neurology-Neurosurgery, University Hospital, Petersgraben 4, 4031 Basel, Switzerland
    J Neurol 252:iii1-iii2. 2005
  3. ncbi Genomics and proteomics: role in the management of multiple sclerosis
    Ludwig Kappos
    Outpatient Clinic Neurology Neurosurgery, University Hospital, Petersgraben 4, 4031 Basel, Switzerland
    J Neurol 252:iii21-iii27. 2005
    ..These data may help us approach the goal of a really "individualised therapy" with increased efficacy, reduced adverse drug reactions and more efficient use of health care resources...
  4. ncbi Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS
    L Kappos
    University of Basel, Basel, Switzerland
    Neurology 67:944-53. 2006
    ..c.) interferon (IFN) beta-1a in relapsing-remitting multiple sclerosis (RRMS)...
  5. ncbi Effect of BG-12 on contrast-enhanced lesions in patients with relapsing--remitting multiple sclerosis: subgroup analyses from the phase 2b study
    Ludwig Kappos
    Department of Neurology, University Hospital Basel, Basel, Switzerland
    Mult Scler 18:314-21. 2012
    ....
  6. ncbi Modeling the cumulative genetic risk for multiple sclerosis from genome-wide association data
    Joanne H Wang
    Department of Neurology, University of California San Francisco, San Francisco, CA 94143 0435, USA
    Genome Med 3:3. 2011
    ..Nevertheless, the knowledge of MS genetics remains incomplete, with many risk alleles still to be revealed...
  7. ncbi MRI characteristics are predictive for CDMS in monofocal, but not in multifocal patients with a clinically isolated syndrome
    Jessica M Nielsen
    MS Center, Department of Neurology, VU Medical Center, Amsterdam, The Netherlands
    BMC Neurol 9:19. 2009
    ..Here we assess the predictive value of clinically defined dissemination in space at first presentation for time to clinically definite MS (CDMS)...
  8. ncbi Effect of drugs in secondary disease progression in patients with multiple sclerosis
    Ludwig Kappos
    Departments of Neurology and Research, University Hospitals, Kantonsspital, Petersgraben 4, CH 4031 Basel, Switzerland
    Mult Scler 10:S46-54; discussion S54-5. 2004
    ..The risk-benefit ratio of these cytostatic agents remains controversial. New strategies addressing the important neurodegenerative aspects of the disease are urgently needed...
  9. ncbi Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials
    L Kappos
    Outpatient Clinic Neurology Neurosurgery, University Hospital Basel, Petersgraben 4, 4031 Basel, Switzerland
    Neurology 63:1779-87. 2004
    ..Reasons for this discrepancy were explored in the combined dataset...
  10. ncbi A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis
    Ludwig Kappos
    Department of Neurology, University Hospital, University of Basel, Switzerland
    N Engl J Med 362:387-401. 2010
    ....
  11. ncbi Interferons in multiple sclerosis
    Ludwig Kappos
    Department of Neurology, University Hospitals, Kantonsspital, CH-4031 Basel, Switzerland
    Neurol Clin 23:189-214, vii-viii. 2005
  12. ncbi Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study
    L Kappos
    Department of Neurology and Research, University Hospital Basel, Switzerland
    Neurology 65:40-7. 2005
    ..To determine the incidence and clinical significance of neutralizing antibody (NAb) formation in patients with relapsing multiple sclerosis (MS) who participated in the European Interferon Beta-1a IM Dose-Comparison Study...
  13. ncbi Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial
    Ludwig Kappos
    University Hospital, Basel, Switzerland
    Lancet Neurol 8:987-97. 2009
    ..The 5-year active treatment extension compares the effects of early and delayed treatment with interferon beta-1b on time to clinically definite multiple sclerosis (CDMS) and other disease outcomes, including disability progression...
  14. ncbi Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring
    Ludwig Kappos
    University Hospital, Basel, Switzerland
    Lancet Neurol 6:431-41. 2007
    ..Maintaining clinical vigilance allows for early suspension of natalizumab in potential cases of PML, thereby increasing the opportunity for immune reconstitution, which may improve prognosis if PML is confirmed...
  15. ncbi Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study
    Ludwig Kappos
    Neurology and Department of Research, University Hospital, Basel, Switzerland
    Lancet 370:389-97. 2007
    ..Our aim was to determine whether early initiation of treatment with interferon beta prevents development of confirmed disability in MS...
  16. ncbi Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes
    L Kappos
    University Hospital, Basel, Switzerland
    Neurology 67:1242-9. 2006
    ..To assess efficacy, safety, and tolerability of every-other-day interferon beta-1b treatment in patients with a first clinical event suggestive of multiple sclerosis (MS) (clinically isolated syndrome)...
  17. ncbi Oral fingolimod (FTY720) for relapsing multiple sclerosis
    Ludwig Kappos
    Department of Neurology, University Hospital, Basel, Switzerland
    N Engl J Med 355:1124-40. 2006
    ..Fingolimod (FTY720) is a new oral immunomodulating agent under evaluation for the treatment of relapsing multiple sclerosis...
  18. ncbi Final analysis of the European multicenter trial on IFNbeta-1b in secondary-progressive MS
    L Kappos
    Department of Neurology, University Hospitals Basel, Switzerland
    Neurology 57:1969-75. 2001
    ..The authors analyzed all data collected until closure of the double-blind study to further scrutinize the consistency of the findings...
  19. ncbi Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring
    Ludwig Kappos
    University Hospital, Basel, Switzerland
    Lancet Neurol 10:745-58. 2011
    ....
  20. ncbi Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial
    Ludwig Kappos
    University Hospital, Basel, Switzerland
    Lancet 378:1779-87. 2011
    ..We aimed to assess efficacy and safety of two dose regimens of the humanised anti-CD20 monoclonal antibody ocrelizumab in patients with relapsing-remitting multiple sclerosis...
  21. ncbi Alternatives to current disease-modifying treatment in MS: what do we need and what can we expect in the future?
    Ludwig Kappos
    Department of Neurology, University Hospital, Kantonsspital, 4031, Basel, Switzerland
    J Neurol 251:v57-v64. 2004
    ....
  22. ncbi Lack of association between antimyelin antibodies and progression to multiple sclerosis
    Jens Kuhle
    Department of Research, University Hospital, Basel, Switzerland
    N Engl J Med 356:371-8. 2007
    ..An increased risk of progression to clinically definite multiple sclerosis in patients with serum antibodies against myelin oligodendrocyte glycoprotein (MOG) and myelin basic protein (MBP) has been reported...
  23. ncbi Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study
    Ludwig Kappos
    University Hospital Basel, Basel, Switzerland
    Lancet 372:1463-72. 2008
    ..Oral fumarate (BG00012) might have dual anti-inflammatory and neuroprotective effects. Our aim was to assess the efficacy and safety of BG00012 in patients with relapsing-remitting multiple sclerosis...
  24. ncbi Effect of immunomodulatory medication on regional gray matter loss in relapsing-remitting multiple sclerosis--a longitudinal MRI study
    Kerstin Bendfeldt
    Medical Image Analysis Centre MIAC, University Hospital Basel, Basel, Switzerland
    Brain Res 1325:174-82. 2010
    ..This is the first longitudinal study investigating the effects of IMs on GM in RRMS. Results suggest differences in the dynamics of regional GM volume atrophy in differentially treated or untreated RRMS patients...
  25. ncbi Spatiotemporal distribution pattern of white matter lesion volumes and their association with regional grey matter volume reductions in relapsing-remitting multiple sclerosis
    Kerstin Bendfeldt
    Medical Image Analysis Center, University Hospital Basel, CH 4031 Basel, Switzerland
    Hum Brain Mapp 31:1542-55. 2010
    ..The different spatiotemporal distribution patterns of patients with progressive compared to patients with non-progressive WM lesions suggest differences in the dynamics of pathogenesis...
  26. ncbi Antimyelin antibodies in clinically isolated syndromes correlate with inflammation in MRI and CSF
    Jens Kuhle
    Department of Neurology, University Hospital Basel, Petersgraben 4, 4031 Basel, Switzerland
    J Neurol 254:160-8. 2007
    ....
  27. ncbi Antigen-specific adaptive immune responses in fingolimod-treated multiple sclerosis patients
    Matthias Mehling
    Department of Neurology, Clinical Neuroimmunology Laboratory, University Hospital Basel, Switzerland
    Ann Neurol 69:408-13. 2011
    ..These results indicate that fingolimod-treated individuals can mount vaccine-specific adaptive immune responses comparable to healthy controls...
  28. ncbi Natalizumab alters transcriptional expression profiles of blood cell subpopulations of multiple sclerosis patients
    Raija L P Lindberg
    Clinical Neuroimmunology Laboratory, Departments of Research and Neurology, University Hospital Basel, Switzerland
    J Neuroimmunol 194:153-64. 2008
    ..Understanding these different gene effects and their interrelationships will provide more insights into additional mechanisms of action of natalizumab and possibly allow better prediction of adverse events...
  29. ncbi Midregional pro-atrial natriuretic peptide and outcome in patients with acute ischemic stroke
    Mira Katan
    Department of Endocrinology, University Hospital Basel, Basel, Switzerland
    J Am Coll Cardiol 56:1045-53. 2010
    ..The purpose of this study was to examine the prognostic value of midregional pro-atrial natriuretic peptide (MR-proANP) in patients with acute ischemic stroke...
  30. ncbi Longitudinal gray matter changes in multiple sclerosis-Differential scanner and overall disease-related effects
    Kerstin Bendfeldt
    Medical Image Analysis Center MIAC, University Hospital Basel, CH 4031 Basel, Switzerland
    Hum Brain Mapp 33:1225-45. 2012
    ..These results suggest that the effects of different scanners on longitudinal GM volume differences were rather small and thus allow pooling of MR data and subsequent combined image analysis. Hum Brain Mapp, 2011. © 2011 Wiley-Liss, Inc...
  31. ncbi SWiss Atorvastatin and interferon Beta-1b trial In Multiple Sclerosis (SWABIMS)--rationale, design and methodology
    Christian P Kamm
    Department of Neurology, Inselspital, Bern University Hospital, and University of Bern, Switzerland
    Trials 10:115. 2009
    ....
  32. ncbi Multivariate pattern classification of gray matter pathology in multiple sclerosis
    Kerstin Bendfeldt
    Medical Image Analysis Center MIAC, University Hospital Basel, CH 4031 Basel, Switzerland
    Neuroimage 60:400-8. 2012
    ....
  33. ncbi Mannose-binding lectin deficiency is associated with smaller infarction size and favorable outcome in ischemic stroke patients
    Michael Osthoff
    Laboratory of Clinical Immunology, Department of Biomedicine and Clinic for Internal Medicine, University Hospital Basel, Basel, Switzerland
    PLoS ONE 6:e21338. 2011
    ....
  34. ncbi Therapy-induced plasticity of cognitive functions in MS patients: insights from fMRI
    Iris Katharina Penner
    Department of Cognitive Psychology and Methodology, University of Basel, Switzerland
    J Physiol Paris 99:455-62. 2006
    ..Results of a study on correlating the effects of cognitive training with changes in brain organization in patients with mild to severe cognitive impairment will be reported...
  35. ncbi Altered expression of miR-17-5p in CD4+ lymphocytes of relapsing-remitting multiple sclerosis patients
    Raija L P Lindberg
    Clinical Neuroimmunology, Department of Biomedicine and Neurology, University Hospital Basel, Basel, Switzerland
    Eur J Immunol 40:888-98. 2010
    ..Our findings support the role of miRNA-dependent regulatory mechanisms in the immunopathogenesis of MS...
  36. ncbi A highly sensitive electrochemiluminescence immunoassay for the neurofilament heavy chain protein
    Jens Kuhle
    Clinical Neuroimmunology, Neurology and Department of Biomedicine, University Hospital Basel, Switzerland
    J Neuroimmunol 220:114-9. 2010
    ..Electrochemiluminescence (ECL) based assays are known to be of superior sensitivity and require less sample volume than conventional ELISAs...
  37. ncbi Fingolimod for multiple sclerosis: mechanism of action, clinical outcomes, and future directions
    Matthias Mehling
    Department of Neurology and Department of Biomedicine, University Hospital Basel, Petersgraben, Switzerland
    Curr Neurol Neurosci Rep 11:492-7. 2011
    ..Overall, in clinical studies fingolimod was well tolerated and had a favorable safety profile. In follow-up studies with continuous fingolimod, treatment showed sustained efficacy while being well tolerated...
  38. ncbi Relation between functional brain imaging, cognitive impairment and cognitive rehabilitation in patients with multiple sclerosis
    Iris Katharina Penner
    University of Basel, Dept of Cognitive Psychology and Methodology, Missionsstr 60 62, 4055, Basel, Switzerland
    J Neurol 254:II53-7. 2007
    ....
  39. ncbi Combined evoked potentials as markers and predictors of disability in early multiple sclerosis
    Regina Schlaeger
    Department of Neurology, University Hospital Basel, Switzerland
    Clin Neurophysiol 123:406-10. 2012
    ..To prospectively assess combined evoked potentials (EP) as markers and predictors of the disease course of early MS over 3 years...
  40. ncbi Atrophy is detectable within a 3-month period in untreated patients with active relapsing remitting multiple sclerosis
    Martin Hardmeier
    MS MRI Evaluation Centre Basel, Basel, Switzerland
    Arch Neurol 60:1736-9. 2003
    ..Brain parenchymal fraction might be a promising measure in future phase 2 studies of agents, with an expected effect on tissue-destructive pathologic mechanisms of MS...
  41. ncbi Monoclonal antibodies and recombinant immunoglobulins for the treatment of multiple sclerosis
    Henrik Gensicke
    Neurology, Department of Medicine, University Hospital Basel, Basel, Switzerland
    CNS Drugs 26:11-37. 2012
    ....
  42. ncbi Copeptin: a novel, independent prognostic marker in patients with ischemic stroke
    Mira Katan
    Department of Endocrinology, University Hospital Basel, Switzerland
    Ann Neurol 66:799-808. 2009
    ..Vasopressin is a stress hormone. Its production rate is mirrored in circulating levels of copeptin, a fragment of provasopressin. We evaluated the prognostic value of copeptin in acute stroke patients...
  43. ncbi Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis
    M Mehling
    Department of Neurology, University Hospitals Basel, Petersgraben 4, CH 4031 Basel, Switzerland
    Neurology 75:403-10. 2010
    ..In this study, we determined the phenotype and frequency of Th17 cells in blood of untreated, FTY720-treated, and interferon-beta (IFNbeta)-treated patients with MS and healthy donors...
  44. ncbi Rate of brain atrophy in relapsing MS decreases during treatment with IFNbeta-1a
    M Hardmeier
    MS MRI Evaluation Centre Basel, University Hospitals Basel, Switzerland
    Neurology 64:236-40. 2005
    ..The atrophy rate reduction observed after treatment month 4 may reflect a beneficial but partial effect of interferon beta-1a and was sustained over the 3-year study period...
  45. ncbi The Fatigue Scale for Motor and Cognitive Functions (FSMC): validation of a new instrument to assess multiple sclerosis-related fatigue
    I K Penner
    Department of Cognitive Psychology and Methodology, University of Basel, Basel, Switzerland
    Mult Scler 15:1509-17. 2009
    ..In conclusion, the FSMC is a new scale that has undergone validation based on a large sample of patients and that provides differential quantification and graduation of cognitive and motor fatigue...
  46. ncbi Retraining attention in MS
    Iris Katharina Penner
    Department of Cognitive Psychology and Methodology, University of Basel, Missionsstr 60 62, 4055 Basel, Switzerland
    J Neurol Sci 245:147-51. 2006
    ....
  47. ncbi Association of regional gray matter volume loss and progression of white matter lesions in multiple sclerosis - A longitudinal voxel-based morphometry study
    Kerstin Bendfeldt
    Department of Neuroradiology, University Hospital Basel, Switzerland
    Neuroimage 45:60-7. 2009
    ..The present study suggests that the progression of regional GM volume reductions is associated with WM lesion progression and occurs predominantly in fronto-temporal cortical areas...
  48. ncbi Multiple sclerosis as a generalized CNS disease--comparative microarray analysis of normal appearing white matter and lesions in secondary progressive MS
    Raija L P Lindberg
    Clinical Neuroimmunology Laboratory, Departments of Research and Neurology, University Hospitals Basel, Pharmazentrum, Klingelbergstrasse 50, CH 4056 Basel, Switzerland
    J Neuroimmunol 152:154-67. 2004
    ....
  49. ncbi Working memory training in patients with multiple sclerosis - comparison of two different training schedules
    Annamarie Vogt
    Department of Cognitive Psychology and Methodology, University of Basel, Basel CH 4055, Switzerland
    Restor Neurol Neurosci 27:225-35. 2009
    ..Evaluation of two different training schedules of a computer based working memory training (BrainStim) in patients with multiple sclerosis (MS)...
  50. ncbi Non-communicating syringomyelia: a feature of spinal cord involvement in multiple sclerosis
    Katrin Weier
    Department of Neurology Neuroradiology, University Hospital Basel, Petersgraben 4, CH 4031 Basel, Switzerland
    Brain 131:1776-82. 2008
    ..We confirm that NCS may occur in MS patients with spinal cord pathology. It can be a subtle finding without clinical correlates. Syrinx formations are more likely to be a consequence of MS cord pathology than a coincidental finding...
  51. ncbi Vancouver Consortium of MS Centers' Magnetic Resonance Imaging Guidelines
    Ernst-Wilhelm Radue
    Kantonsspital Basel, Abtl. Neuroradiologie, 4031 Basel, Switzerland
    Int MS J 10:131-3. 2003
    ..MRI aids our understanding of MS and management of patients...
  52. ncbi Transcriptional profiling of multiple sclerosis: towards improved diagnosis and treatment
    Raija L P Lindberg
    Outpatient Clinic Neurology Neurosurgery and Department of Research, Pharmazentrum University Hospital Basel, Petersgraben 4, 4031 Basel, Switzerland
    Expert Rev Mol Diagn 6:843-55. 2006
    ..The emerging potential of microarray technology to define gene signatures, diagnostic and prognostic markers for disease course, and treatment response in multiple sclerosis will be discussed...
  53. ncbi Altered functional adaptation to attention and working memory tasks with increasing complexity in relapsing-remitting multiple sclerosis patients
    Michael Amann
    Department of Neuroradiology, University Hospital Basel, CH 4031 Switzerland
    Hum Brain Mapp 32:1704-19. 2011
    ..Our results indicate that, in MS, functional adaptation patterns can be found which precede clinical evidence of apparent cognitive decline...
  54. ncbi Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis
    Ernst Wilhelm Radue
    Medical Image Analysis Center, University Hospital Basel, Schanzenstrasse 55, 1st Floor, CH 4031, Basel, Switzerland
    J Neurol Sci 292:28-35. 2010
    ....
  55. ncbi [Stress-related vertical double vision and ptosis]
    A M Palmowski-Wolfe
    Augenklinik, Universitatsspital Basel, Basel, Schweiz
    Ophthalmologe 106:52-4. 2009
    ..This treatment approach led to a reduction of tumor volume in our patient as well as clinical improvement followed by stabilization...
  56. ncbi MS quality of life, depression, and fatigue improve after mindfulness training: a randomized trial
    P Grossman
    Department of Psychosomatic Medicine, Division of Internal Medicine, University Hospital Basel, Hebelstrasse 2, Basel, Switzerland
    Neurology 75:1141-9. 2010
    ..We examined effects of a mindfulness-based intervention (MBI) compared to usual care (UC) upon HRQOL, depression, and fatigue among adults with relapsing-remitting or secondary progressive MS...
  57. ncbi Retinal vessels in patients with multiple sclerosis: baseline diameter and response to flicker light stimulation
    K Gugleta
    University Eye Clinic Basel, Basel, Switzerland
    Klin Monbl Augenheilkd 226:272-5. 2009
    ..Transparency of ocular media enables the precise quantitative analysis of vessels of retina, a neuronal tissue which can be affected by multiple sclerosis (MS)...
  58. ncbi Neurofilament heavy chain in CSF correlates with relapses and disability in multiple sclerosis
    J Kuhle
    Department of Biomedicine and Neurology, University Hospital Basel, CH 4031 Basel, Switzerland
    Neurology 76:1206-13. 2011
    ..We sought to discover whether CSF levels of neurofilament heavy chain protein (NfH(SMI35)) correlate with disability, disease activity, or specific stages of MS...
  59. ncbi Fatigue in multiple sclerosis: relation to depression, physical impairment, personality and action control
    I K Penner
    Department of Cognitive Psychology and Methodology, University of Basel, Switzerland
    Mult Scler 13:1161-7. 2007
    ..Decreased levels of action control imply attentional and motivational deficits and were only found in fatigued MS patients. Our study indicates that motivational disturbances might be specific for MS related fatigue...
  60. ncbi Neuropsychological dysfunction, depression, physical disability, and coping processes in families with a parent affected by multiple sclerosis
    M M Ehrensperger
    Memory Clinic, Department of Geriatrics, University Hospital Basel, Switzerland
    Mult Scler 14:1106-12. 2008
    ..Most studies analyzing factors that influence coping abilities in families with a member affected with MS used questionnaires to assess this ability...
  61. ncbi [Neurological complications of HIV infection. Review: new diagnostic, therapeutic and prognostic aspects]
    A J Radziwill
    Neurologische Universitätsklinik und Poliklinik, Kantonsspital Basel
    Schweiz Med Wochenschr 130:457-70. 2000
    ..The prognosis of different HIV-associated neurological diseases has considerably improved, as recently shown in the case, for example, of progressive multifocal leucoencephalopathy...
  62. ncbi Swallowing abnormalities in multiple sclerosis: correlation between videofluoroscopy and subjective symptoms
    W Wiesner
    Institute of Diagnostic Radiology, University Hospital of Basel, Petersgraben 4, 4031 Basel, Switzerland
    Eur Radiol 12:789-92. 2002
    ..Swallowing abnormalities seem to be much more frequent in patients with MS than generally believed and they may easily be missed clinically as long as the patients do not aspirate...
  63. ncbi Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group
    L Kappos
    Department of Neurology, Kantonsspital, Basel, Switzerland
    Lancet 353:964-9. 1999
    ..To investigate the prognostic value of gadolinium-enhanced MRI, we did a meta-analysis of longitudinal MRI studies...
  64. ncbi Dimethyl fumarate for multiple sclerosis
    Athina Papadopoulou
    University of Basel, Department of Neurology, Petersgraben 4, CH 4031, Basel, Switzerland
    Expert Opin Investig Drugs 19:1603-12. 2010
    ..One of these emerging drugs is BG00012 (BG-12), a fumaric acid ester (FAE). Its active agent, dimethyl fumarate had first been included in FAE treatments for psoriasis...
  65. ncbi Optimizing brain MRI protocols in the follow-up of patients with multiple sclerosis T2-weighted MRI of the brain after the administration of gadopentetate dimeglumine
    Christian A Taschner
    Institute of Neuroradiology, Department of Medical Radiology, University Hospital Basel, CH 4031 Basel, Switzerland
    Magn Reson Imaging 23:469-74. 2005
    ..Acquisition of T2w MR images immediately after the administration of gadolinium DTPA allows for shorter examination time and assures sufficient time for contrast enhancement in cerebral lesions with a disrupted blood-brain barrier...
  66. ncbi Rigidity of retinal vessels in patients with multiple sclerosis
    A Kochkorov
    University Eye Clinic, University Hospital Basel, Basel, Switzerland
    Klin Monbl Augenheilkd 226:276-9. 2009
    ....
  67. ncbi Indication for psychotherapy in offspring of a parent affected by a chronic somatic disease (e.g. multiple sclerosis)
    B Steck
    Department of Child and Adolescent Psychiatry, University of Basel, Basel, Switzerland
    Psychopathology 38:38-48. 2005
    ..In our sample, half of the children and adolescents were estimated to benefit from individual psychotherapy, which might enhance their ability to cope with the parental illness...
  68. ncbi FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis
    M Mehling
    Department of Biomedicine and Neurology, University Hospital Basel, Petersgraben 4, CH 4031 Basel, Switzerland
    Neurology 71:1261-7. 2008
    ..Little is known about the phenotype and function of T cells remaining in peripheral blood during long-term FTY720 treatment...
  69. ncbi Analysis of impairment related functional architecture in MS patients during performance of different attention tasks
    Iris Katharina Penner
    University of Basel, Dept of Cognitive Psychology and Methodology, Missionsstr 60 62, 4055 Basel, Switzerland
    J Neurol 250:461-72. 2003
    ..The extent of compensation seems to depend on the brain's capacity to access additional brain structures. Exhaustion of this capacity may finally lead to severe cognitive impairment...
  70. ncbi Can the Expanded Disability Status Scale be assessed by telephone?
    J Lechner-Scott
    Department of Neurology, Kantonspital Basel, Switzerland
    Mult Scler 9:154-9. 2003
    ..The telephone questionnaire is a valid tool to assess EDSS score in cases where the patient is unable to continue visiting a study centre or in long-term follow-up of trial participants...
  71. ncbi Disease variables and depression affecting the process of coping in families with a somatically ill parent
    B Steck
    Child and Adolescent Psychiatry, University of Basel, Basel, Switzerland
    Psychopathology 40:394-404. 2007
    ....
  72. ncbi Gender-specific differences in the process of coping in families with a parent affected by a chronic somatic disease (e.g. multiple sclerosis)
    B Steck
    Department of Child and Adolescent Psychiatry, University of Basel, Switzerland
    Psychopathology 34:236-44. 2001
    ..This is not the case for healthy fathers and sons. Gender seems to be an important moderating factor in chronic parental disease and it has complex effects on the coping capacity of children...
  73. ncbi Endonasal surgery for contact point headaches: a 10-year longitudinal study
    Antje Welge-Luessen
    Department of Otorhinolaryngology, University of Basel, Kantonsspital, Petersgraben 4, CH 4031 Basel, Switzerland
    Laryngoscope 113:2151-6. 2003
    ..Some migraine and cluster headaches may be triggered by stimulation of intranasal contact points via the trigeminovascular system. Endonasal surgery is successful in some patients, but long-term outcomes have not been reported...
  74. ncbi Oculopharyngeal muscular dystrophy - an under-diagnosed disorder?
    Stephan Ruegg
    Department of Neurology, University Hospital Basel, Basel, Switzerland
    Swiss Med Wkly 135:574-86. 2005
    ....
  75. ncbi Mental health problems in children of somatically ill parents, e.g. multiple sclerosis
    Barbara Steck
    Child and Adolescent Psychiatry, University of Basel, Schaffhauserrheinweg 55, 4058 Basel, Switzerland
    Eur Child Adolesc Psychiatry 16:199-207. 2007
    ....
  76. ncbi Reconsidering clinical outcomes in Multiple Sclerosis: relapses, impairment, disability and beyond
    M D'Souza
    Department of Neurology, University Basel, Switzerland
    J Neurol Sci 274:76-9. 2008
    ..As there is yet no scale or assessment, which objectively covers all major issues, it is recommended to use multiple instruments and endpoints as secondary outcome measures...
  77. ncbi Increased levels of inflammatory chemokines in amyotrophic lateral sclerosis
    J Kuhle
    Department of Neurology, University Hospital Basel, Basel, Switzerland
    Eur J Neurol 16:771-4. 2009
    ..Inflammation has been observed in CNS tissue in ALS patients. We investigated the expression and prognostic relevance of proinflammatory chemokines in ALS...
  78. ncbi Extraocular blood flow and endothelin-1 plasma levels in patients with multiple sclerosis
    Mona Pache
    University Eye Clinic Basel, University Hospital Basel, Basel, Switzerland
    Eur Neurol 49:164-8. 2003
    ..0 +/- 0.4 pg/ml, range 1.1-2.8 vs. 1.5 +/- 0.2 pg/ml, range 0.9-2.0; p < 0.001). Moreover, the patients exhibited significant alterations of extraocular blood flow. The role of ET-1 in the inflammatory process remains to be clarified...
  79. ncbi The expression profile of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in lesions and normal appearing white matter of multiple sclerosis
    R L Lindberg
    Department of Research, University Hospitals Basel, Switzerland
    Brain 124:1743-53. 2001
    ..We hypothesize that an imbalance between MMP and TIMP expression may cause a persistent proteolytic overactivity in multiple sclerosis, that may be a factor for continuous tissue destruction, and hence for secondary disease progression...
  80. ncbi Interleukin 15 stimulates production of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 by human peripheral blood mononuclear cells
    C S Constantinescu
    Departments of Neurology and Research, University Hospital, Basle, Switzerland
    Cytokine 13:244-7. 2001
    ..IL-15 led to a dose-dependent increase of the MMP-9/TIMP-1 ratio as a measure for increased proteolytic capacity. We conclude that IL-15 mediates its effects in inflammation in part through MMP-9...
  81. ncbi Matrix metalloproteinases: multifunctional effectors of inflammation in multiple sclerosis and bacterial meningitis
    D Leppert
    Department of Neurology, University Hospitals, Petersgraben 4, CH 4031, Basel, Switzerland
    Brain Res Brain Res Rev 36:249-57. 2001
    ..MMP inhibitors with selective target profiles offer the possibility of a more efficient therapy of MS and BM and may enter clinical trials in the near future...
  82. ncbi Meningoradiculitis associated with giant cell arteritis
    U Roelcke
    Department of Neurology, Cantonal Hospital, Aarau, Switzerland
    Neurology 59:1811-2. 2002
  83. ncbi Evoked potentials for evaluation of multiple sclerosis
    P Fuhr
    Department of Neurology, University of Basel, Basel, Switzerland
    Clin Neurophysiol 112:2185-9. 2001
    ....
  84. ncbi Visual and motor evoked potentials in the course of multiple sclerosis
    P Fuhr
    Department of Neurology, University of Basel, Switzerland
    Brain 124:2162-8. 2001
    ....
  85. ncbi Pattern of macular thickness changes measured by ocular coherence tomography in patients with multiple sclerosis
    K Gugleta
    Outpatient Neurology Clinic, University Hospital Basel, Basel, Switzerland
    Klin Monbl Augenheilkd 225:408-12. 2008
    ..An analysis of the pattern of retinal thickness changes in macula in patients with multiple sclerosis (MS) was performed...
  86. ncbi Gelatinase B [matrix metalloproteinase (MMP)-9] and collagenases (MMP-8/-13) are upregulated in cerebrospinal fluid during aseptic and bacterial meningitis in children
    R L P Lindberg
    Clinical Neuroimmunology Laboratory, Department of Research and Neurology, University Hospital of Basel, Basel, Switzerland
    Neuropathol Appl Neurobiol 32:304-17. 2006
    ..The present data support the concept that broad-spectrum enzyme inhibition targeting gelatinases and collagenases is a potential strategy for adjunctive therapy in infectious meningitis...
  87. ncbi Clinical and immune responses correlate in glatiramer acetate therapy of multiple sclerosis
    C Weder
    Department of Neurology, University Hospital, Basle, Switzerland
    Eur J Neurol 12:869-78. 2005
    ..These associations suggest a possible causal relationship between immunological and clinical responses to GA therapy. Primary proliferation assays may thus be a useful marker for treatment response...
  88. ncbi Is natalizumab overshooting its rebound?
    Robert J Fox
    Neurology 70:1073-4. 2008
  89. ncbi The Janus face of CNS-directed autoimmune response: a therapeutic challenge
    Ludwig Kappos
    Brain 125:2379-80. 2002
  90. ncbi Anti-interferon-beta neutralising activity is not entirely mediated by antibodies
    Francesca Gilli
    Centro di Riferimento Regionale Sclerosi Multipla CReSM and Neurobiologia Clinica, ASO S Luigi Gonzaga, Orbassano, Torino, Italy
    J Neuroimmunol 192:198-205. 2007
    ..A minority of IFNbeta treated patients have a non-antibody mediated neutralising activity, which competitively inhibits the bioactivity both in vitro and in vivo...
  91. ncbi Magnetic resonance imaging effects of interferon beta-1b in the BENEFIT study: integrated 2-year results
    Frederik Barkhof
    Department of Diagnostic Radiology and Image Analysis Center, Vrije Universiteit Medical Center, PO Box 7057, 1007 MB Amsterdam, The Netherlands
    Arch Neurol 64:1292-8. 2007
    ....
  92. ncbi Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study
    Benjamin M Segal
    Department of Neurology, Holtom Garrett Programme in Neuroimmunology, University of Michigan, Ann Arbor, MI 48109 2200, USA
    Lancet Neurol 7:796-804. 2008
    ....
  93. ncbi Pharmacodynamics of interferon beta in multiple sclerosis patients with or without serum neutralizing antibodies
    Carolina Scagnolari
    Dept of Experimental Medicine Virology Section, La Sapienza University, Rome, Italy
    J Neurol 254:597-604. 2007
    ..In summary, our findings confirm that NABs affect absolute concentrations of IFN-beta induced markers and suggest that such an effect occurs in a titer-dependent manner...
  94. ncbi Secondary progressive multiple sclerosis: current knowledge and future challenges
    Marco Rovaris
    Neuroimaging Research Unit, Scientific Institute and University Ospedale San Raffaele, Milan, Italy
    Lancet Neurol 5:343-54. 2006
    ....
  95. ncbi Health-related quality of life in multiple sclerosis: effects of natalizumab
    Richard A Rudick
    Department of Neurology, Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Ann Neurol 62:335-46. 2007
    ..To report the relationship between disease activity and health-related quality of life (HRQoL) in relapsing multiple sclerosis, and the impact of natalizumab...
  96. ncbi Subgroups of the BENEFIT study: risk of developing MS and treatment effect of interferon beta-1b
    Chris Polman
    Vrije Universiteit Medical Centre, Amsterdam, The Netherlands
    J Neurol 255:480-7. 2008
    ..The BENEFIT study examined interferon beta (IFNB)-1b treatment in patients with clinically isolated syndrome (CIS) and > or = 2 clinically silent brain MRI lesions...
  97. ncbi A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis
    Chris H Polman
    Vrije Universiteit Medical Center, Amsterdam, The Netherlands
    N Engl J Med 354:899-910. 2006
    ..Natalizumab is the first alpha4 integrin antagonist in a new class of selective adhesion-molecule inhibitors. We report the results of a two-year phase 3 trial of natalizumab in patients with relapsing multiple sclerosis...
  98. ncbi Natalizumab: targeting alpha4-integrins in multiple sclerosis
    Britta Engelhardt
    Theodor Kocher Institute, University of Bern, Bern, Switzerland
    Neurodegener Dis 5:16-22. 2008
    ..In this review, we discuss the basic mechanism of action, key clinical results of clinical trials and the emerging indication of natalizumab in MS...
  99. ncbi Re: Neutralizing antibodies to interferon beta-1b are not associated with disease worsening in multiple sclerosis
    Rachel Farrell
    J Int Med Res 36:204-8; author reply 208-10. 2008
  100. ncbi The distribution of magnetic resonance imaging response to interferonbeta-1b in multiple sclerosis
    Maria Pia Sormani
    Neuroimaging Research Unit, Dept. of Neurology, Scientific Institute and University Ospedale San Raffaele, Via Olgettina 60, 20132 Milan, Italy
    J Neurol 252:1455-8. 2005
    ..This study might be regarded as a first step toward the definition of markers potentially useful to identify IFNbeta treatment responders and non-responders with regard to T2 lesion activity...
  101. ncbi European validation of a standardized clinical description of multiple sclerosis
    Maria Pia Amato
    Department of Neurological Sciences, University of Florence, Viale Morgagni, 85, 50134, Florence, Italy
    J Neurol 251:1472-80. 2004
    ....